These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12660398)

  • 21. Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
    Goldberg SV; Duchin JS; Shields T; Nolan CM
    Am J Respir Crit Care Med; 1999 Aug; 160(2):508-12. PubMed ID: 10430721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
    Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
    Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Can Commun Dis Rep; 2001 Jul; 27(13):114-6. PubMed ID: 11443837
    [No Abstract]   [Full Text] [Related]  

  • 25. Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lambert LA; Ijaz K; Navin TR
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):230; author reply 230-1. PubMed ID: 15732748
    [No Abstract]   [Full Text] [Related]  

  • 26. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 28. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 29. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of tuberculosis].
    Jentgens H
    Dtsch Med Wochenschr; 1974 Aug; 99(32):1627-30. PubMed ID: 4135677
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances and principles in tuberculostatic therapy].
    Bethge H
    Internist (Berl); 1971 Aug; 12(8):328-31. PubMed ID: 4328130
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
    Ijaz K; McElroy PD; Jereb J; Navin TR; Castro KG
    Clin Infect Dis; 2007 Feb; 44(3):464-5; author reply 465. PubMed ID: 17205462
    [No Abstract]   [Full Text] [Related]  

  • 34. Modern treatment of tuberculosis.
    Dutt AK; Stead WW
    Compr Ther; 1982 Sep; 8(9):19-28. PubMed ID: 7140206
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection.
    Castro KG; Jereb JA; Koppaka VR; Cohn DL
    Chest; 2003 Mar; 123(3):967. PubMed ID: 12628913
    [No Abstract]   [Full Text] [Related]  

  • 37. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
    Chakraborty S; Rhee KY
    Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-tuberculosis chemotherapy and management of adverse reactions].
    Kuwabara K
    Nihon Rinsho; 2011 Aug; 69(8):1389-93. PubMed ID: 21838035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.